Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial - PubMed (original) (raw)
Randomized Controlled Trial
. 2010 May 1;16(9):2634-45.
doi: 10.1158/1078-0432.CCR-09-2042. Epub 2010 Apr 20.
Volkmar Müller, Liling Zhang, Thomas Rau, Sibylle Loibl, Martina Komor, Marc Roller, Jens Huober, Tanja Fehm, Iris Schrader, Jörn Hilfrich, Frank Holms, Hans Tesch, Holger Eidtmann, Michael Untch, Gunter von Minckwitz, Klaus Pantel
Affiliations
- PMID: 20406831
- DOI: 10.1158/1078-0432.CCR-09-2042
Randomized Controlled Trial
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial
Sabine Riethdorf et al. Clin Cancer Res. 2010.
Abstract
Purpose: This study was aimed at detecting and characterizing circulating tumor cells (CTC) before and after neoadjuvant therapy (NT) in the peripheral blood of patients with breast cancer.
Experimental design: The clinical trial GeparQuattro incorporated NT approaches (epirubicin/cyclophosphamide prior to randomization to docetaxel alone, docetaxel in combination with capecitabine, or docetaxel followed by capecitabine) and additional trastuzumab treatment for patients with HER2-positive tumors. We used the Food and Drug Administration-approved CellSearch system for CTC detection and evaluation of HER2 expression and developed HER2 immunoscoring for CTC.
Results: We detected > or =1 CTC/7.5 mL in 46 of 213 patients (21.6%) before NT and in 22 of 207 patients (10.6%) after NT (P = 0.002). Twenty (15.0%) initially CTC-positive cases were CTC-negative after NT, whereas 11 (8.3%) cases were CTC-positive after NT, although no CTC could be found before NT. CTC detection did not correlate with primary tumor characteristics. Furthermore, there was no association between tumor response to NT and CTC detection. HER2-overexpressing CTC were observed in 14 of 58 CTC-positive patients (24.1%), including 8 patients with HER2-negative primary tumors and 3 patients after trastuzumab treatment. CTC scored HER2-negative or weakly HER2-positive before or after NT were present in 11 of 21 patients with HER2-positive primary tumors. HER2 overexpression on CTC was restricted to ductal carcinomas and associated with high tumor stage (P = 0.002).
Conclusion: CTC number was low in patients with primary breast cancer. The decrease in CTC incidence during treatment was not correlated with standard clinical characteristics and primary tumor response. Information on the HER2 status of CTC might be helpful for stratification and monitoring of HER2-directed therapies.
Copyright 2010 AACR.
Similar articles
- Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G. Untch M, et al. J Clin Oncol. 2010 Apr 20;28(12):2024-31. doi: 10.1200/JCO.2009.23.8451. Epub 2010 Mar 22. J Clin Oncol. 2010. PMID: 20308670 Clinical Trial. - Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Untch M. von Minckwitz G, et al. J Clin Oncol. 2010 Apr 20;28(12):2015-23. doi: 10.1200/JCO.2009.23.8303. Epub 2010 Mar 22. J Clin Oncol. 2010. PMID: 20308671 Clinical Trial. - Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
von Minckwitz G, Darb-Esfahani S, Loibl S, Huober J, Tesch H, Solbach C, Holms F, Eidtmann H, Dietrich K, Just M, Clemens MR, Hanusch C, Schrader I, Henschen S, Hoffmann G, Tiemann K, Diebold K, Untch M, Denkert C. von Minckwitz G, et al. Breast Cancer Res Treat. 2012 Apr;132(3):863-70. doi: 10.1007/s10549-011-1621-0. Epub 2011 Jun 12. Breast Cancer Res Treat. 2012. PMID: 21667238 - Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer.
Chang HR. Chang HR. Cancer. 2010 Jun 15;116(12):2856-67. doi: 10.1002/cncr.25120. Cancer. 2010. PMID: 20564392 Review. - [Docetaxel (Taxotere) in combination with anthracycline, capecitabin (Xeloda) and new drugs].
Galligioni E. Galligioni E. Tumori. 2001 Jan-Feb;87(1 Suppl 2):S1-9. Tumori. 2001. PMID: 11357871 Review. Italian. No abstract available.
Cited by
- A Review of Circulating Tumour Cell Enrichment Technologies.
Rushton AJ, Nteliopoulos G, Shaw JA, Coombes RC. Rushton AJ, et al. Cancers (Basel). 2021 Feb 26;13(5):970. doi: 10.3390/cancers13050970. Cancers (Basel). 2021. PMID: 33652649 Free PMC article. Review. - HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment.
Wang M, Liu Y, Shao B, Liu X, Hu Z, Wang C, Li H, Zhu L, Li P, Yang Y. Wang M, et al. Front Bioeng Biotechnol. 2022 Sep 28;10:1015295. doi: 10.3389/fbioe.2022.1015295. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 36246381 Free PMC article. - Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer.
Gianni C, Palleschi M, Merloni F, Bleve S, Casadei C, Sirico M, Di Menna G, Sarti S, Cecconetto L, Mariotti M, De Giorgi U. Gianni C, et al. Cancers (Basel). 2022 Dec 23;15(1):96. doi: 10.3390/cancers15010096. Cancers (Basel). 2022. PMID: 36612091 Free PMC article. Review. - Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?
Turner N, Pestrin M, Galardi F, De Luca F, Malorni L, Di Leo A. Turner N, et al. Cancers (Basel). 2014 Mar 25;6(2):684-707. doi: 10.3390/cancers6020684. Cancers (Basel). 2014. PMID: 24670368 Free PMC article. - Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions.
Dowling RJO, Sparano JA, Goodwin PJ, Bidard FC, Cescon DW, Chandarlapaty S, Deasy JO, Dowsett M, Gray RJ, Henry NL, Meric-Bernstam F, Perlmutter J, Sledge GW, Thorat MA, Bratman SV, Carey LA, Chang MC, DeMichele A, Ennis M, Jerzak KJ, Korde LA, Lohmann AE, Mamounas EP, Parulekar WR, Regan MM, Schramek D, Stambolic V, Whelan TJ, Wolff AC, Woodgett JR, Kalinsky K, Hayes DF. Dowling RJO, et al. JNCI Cancer Spectr. 2019 Aug 10;3(4):pkz049. doi: 10.1093/jncics/pkz049. eCollection 2019 Dec. JNCI Cancer Spectr. 2019. PMID: 32337478 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous